NewsPronto

 
Men's Weekly

.

ACN Newswire

Read more press releases from ACN Newswire here

Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020

  • Written by ACN Newswire

image

TOKYO, Sep 23, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced new investigational data from two trials under the LEAP (LEnvatinib And Pembrolizumab) clinical program evaluating LENVIMA, the orally available multiple receptor tyrosine kinase...

Read more: Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus...